直接口服抗凝药治疗内脏静脉血栓的疗效与安全性:文献研究的汇总分析
本汇总分析系统检索PubMed、Web of Science和Scopus数据库,纳入16项研究(17个数据集)共648例接受直接口服抗凝药治疗的内脏静脉血栓患者。结果显示任何再通率60.3%、完全再通率51.7%、复发性静脉血栓栓塞2.8%、死亡3.4%、大出血5.8%。作者认为直接口服抗凝药在内脏静脉血栓患者中可能具有良好的安全性和有效性,但需随机研究证实。
要点
- 648例内脏静脉血栓患者接受直接口服抗凝药治疗,任何再通率60.3%,完全再通率51.7%。
- 复发性静脉血栓栓塞2.8%,死亡3.4%,大出血5.8%。
- 年龄增长和癌症影响再通率,肝硬化与大出血和死亡率升高相关。
核心结论
- 本研究结果主要基于观察性研究,提示直接口服抗凝药在内脏静脉血栓患者中可能具有良好的安全性和有效性。
- 需要随机研究证实本研究的发现。
研究设计与样本
- 按照PRISMA指南系统检索PubMed、Web of Science和Scopus数据库的文献研究。
- 共纳入16项研究(17个数据集),648例接受直接口服抗凝药治疗的内脏静脉血栓患者。
- 以加权平均患病率(WMP)及95%CI报告结果,并进行亚组分析和Meta回归以处理异质性及调整潜在混杂因素。
主要发现
- 任何再通率为60.3%(95%CI:41.8%-76.3%;I²=84.9%;P<.001)。
- 完全再通率为51.7%(95%CI:36.0%-67.0%;I²=87.4%;P<.001)。
- 复发性静脉血栓栓塞发生率为2.8%(95%CI:1.4%-5.9%;I²=0%;P=.787)。
- 死亡率为3.4%(95%CI:1.6%-7.3%;I²=13.2%;P=.318)。
- 大出血发生率为5.8%(95%CI:3.7%-8.9%;I²=29.2%;P=.125)。
关键数值与推荐
- 分别分析前瞻性研究、回顾性研究、肝硬化患者研究和门静脉血栓患者研究时,结果一致。
- Meta回归分析显示,年龄增长和癌症影响再通率。
- 肝硬化与大出血率和死亡率升高相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究结果主要基于观察性研究。
- 需要随机研究证实本研究的发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited evidence is available on management of splanchnic vein thrombosis (SVT). OBJECTIVES: This study aimed to evaluate safety and efficacy of direct oral anticoagulants (DOACs) for SVT treatment. METHODS: Studies were systematically searched in the PubMed, Web of Science, and Scopus databases according to PRISMA guidelines. We assessed any recanalization, full recanalization, recurrence, mortality, and major bleeding as outcomes of interest. Results were reported as weighted mean prevalence (WMP) with 95% CI. Subgroup analyses and meta-regressions have been performed to address heterogeneity and adjust for potential confounders. RESULTS: We included a total of 16 studies (17 datasets) on 648 patients with SVT treated with DOACs. We found any recanalization in 60.3% (95% CI: 41.8%-76.3%; I2 = 84.9%; P < .001) and full recanalization in 51.7% (95% CI: 36.0%-67.0%; I2 = 87.4%; P < .001). Recurrent venous thromboembolism occurred in 2.8% (95% CI: 1.4%-5.9%; I2 = 0%; P = .787) and death in 3.4% (95% CI: 1.6%-7.3%; I2 = 13.2%; P = .318) of patients. Major bleeding was reported by 5.8% (95% CI: 3.7%-8.9%; I2 = 29.2%; P = .125) of patients. Results were consistent when separately analyzing prospective studies, retrospective studies, studies on cirrhotic patients, and studies enrolling patients with portal vein thrombosis. Meta-regression analyses showed that an increasing age and cancer impacted the rate of recanalization. Cirrhosis was associated with a higher rate of major bleeding and mortality. CONCLUSION: The results of the present study, mostly based on observational studies, suggest good safety and efficacy profiles of DOACs in patients with SVT. Randomized studies are needed to corroborate our findings.
引用
- Calcaterra I, Tufano A, Strano F, et al. Efficacy and safety of direct oral anticoagulants in splanchnic vein thrombosis: a pooled analysis of literature studies. J Thromb Haemost. 2023. PMID: 37926192. doi:10.1016/j.jtha.2023.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。